BRAF and acute myeloid leukemia: Three fusion genes, CIITA-BCL6, MBNL1-BCL6, and CUX1-BRAF, served as inclusion criteria for one or more clinical trials, and an AML patient had a NUP98-NSD1 gene fusion indicative of poor prognosis [26].